PMID- 9405974
OWN - NLM
STAT- MEDLINE
DCOM- 19980115
LR  - 20181201
IS  - 0018-5043 (Print)
IS  - 0018-5043 (Linking)
VI  - 29
IP  - 10
DP  - 1997 Oct
TI  - Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of 
      monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in 
      vascular endothelial cells.
PG  - 491-5
AB  - The induction of monocyte chemoattractant protein-1 (MCP-1) in vascular 
      endothelial cells is thought to be an initial event in the development of 
      atherosclerotic lesions. Therefore, inhibition of MCP-1 production may exhibit 
      some effects in preventing atherosclerosis. In the present study, we found that 
      10 microM cilostazol, a cAMP phosphodiesterase inhibitor, increased the 
      intracellular cAMP content by a twenty-five times of the basal level and resulted 
      in the reduction of basal MCP-1 release by 41% from 168 +/- 11 ng/24 hr/mg 
      protein to 99 +/- 14 ng/24 hr/mg protein (P < 0.001) from cultured human 
      umbilical vein endothelial cells. Furthermore, 10 microM cilostazol also 
      significantly attenuated the dose-dependent increment of MCP-1 production by 
      tumor necrosis factor-alpha. The inhibition was consistent with the reduction of 
      MCP-1 mRNA level, possibly through reduced activation of transcription factor 
      NF-kappa B level. Similarly, 1 mM dibutyryl cAMP inhibited MCP-1 production in 
      endothelial cells. These data suggest that cilostazol inhibits MCP-1 production 
      through increased intracellular cAMP levels and modulation of its expression in 
      vascular endothelial cells.
FAU - Nishio, Y
AU  - Nishio Y
AD  - Third Department of Medicine, Shiga University of Medical Science, Japan.
FAU - Kashiwagi, A
AU  - Kashiwagi A
FAU - Takahara, N
AU  - Takahara N
FAU - Hidaka, H
AU  - Hidaka H
FAU - Kikkawa, R
AU  - Kikkawa R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Horm Metab Res
JT  - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
      metabolisme
JID - 0177722
RN  - 0 (Chemokine CCL2)
RN  - 0 (NF-kappa B)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tetrazoles)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 63X7MBT2LQ (Bucladesine)
RN  - E0399OZS9N (Cyclic AMP)
RN  - EC 3.1.4.17 (3',5'-Cyclic-AMP Phosphodiesterases)
RN  - N7Z035406B (Cilostazol)
SB  - IM
MH  - 3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors
MH  - Bucladesine/pharmacology
MH  - Cells, Cultured
MH  - Chemokine CCL2/*antagonists & inhibitors/genetics
MH  - Cilostazol
MH  - Cyclic AMP/*biosynthesis
MH  - Endothelium, Vascular/cytology/*drug effects/metabolism
MH  - Humans
MH  - NF-kappa B/antagonists & inhibitors
MH  - Phosphodiesterase Inhibitors/*pharmacology
MH  - Platelet Aggregation Inhibitors/pharmacology
MH  - RNA, Messenger/antagonists & inhibitors
MH  - Tetrazoles/*pharmacology
MH  - Tumor Necrosis Factor-alpha/*metabolism/pharmacology
MH  - Umbilical Veins/cytology/drug effects/metabolism
EDAT- 1997/12/24 00:00
MHDA- 1997/12/24 00:01
CRDT- 1997/12/24 00:00
PHST- 1997/12/24 00:00 [pubmed]
PHST- 1997/12/24 00:01 [medline]
PHST- 1997/12/24 00:00 [entrez]
AID - 10.1055/s-2007-979086 [doi]
PST - ppublish
SO  - Horm Metab Res. 1997 Oct;29(10):491-5. doi: 10.1055/s-2007-979086.